StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Teva Pharma (TEVA) PT Raised to $18 at BofA Securities
May 9, 2024 6:16 AM
BofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $18.00 (from $16.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31
May 8, 2024 4:09 PM
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
May 8, 2024 7:20 AM
Teva Pharma (TEVA) Misses Q1 EPS by 3c
May 8, 2024 7:05 AM
Form 8-K TEVA PHARMACEUTICAL INDU For: May 08
May 8, 2024 7:01 AM
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
May 8, 2024 7:00 AM
Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749
May 8, 2024 6:30 AM
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
May 8, 2024 6:30 AM
Form 10-Q Immuneering Corp For: Mar 31
May 7, 2024 4:10 PM
Form 8-K Immuneering Corp For: May 07
May 7, 2024 4:04 PM
Teva Pharma (TEVA) call put ratio 48 calls to 1 put with focus on May 14 and January 17 calls into quarter results
May 7, 2024 10:36 AM
Teva Pharma (TEVA) call put ratio 52 calls to 1 put into quarter results
May 7, 2024 5:35 AM
